文献速递烧伤创面修复

严重烧伤新型结局指标验证:持续性器官功能障碍+死亡

The initial validation of a novel outcome measure in severe burns- the Persistent Organ Dysfunction +Death: Results from a multicenter evaluation.
PubMed 文献 · Burns · 2020-10-03

本研究为国际多中心前瞻性随机对照试验(RE-ENERGIZE)的二次结局分析,纳入烧伤总面积>20%且随访6个月的患者539例,验证「持续性器官功能障碍+死亡」作为烧伤临床试验结局指标的统计效率。结果显示第14天和第28天该复合结局发生率分别为40%和27%,且可大幅减少所需样本量,提示其作为严重烧伤临床试验复合结局指标具有前景,仍需更大规模验证。

要点

  • 严重烧伤患者中持续性器官功能障碍+死亡第14天发生率为40%,第28天为27%。
  • 有持续性器官功能障碍的存活者死亡率更高、ICU及住院时间更长、生活质量更低。
  • 以28天持续性器官功能障碍+死亡为结局可显著减少临床试验所需样本量。

核心结论

  • 持续性器官功能障碍+死亡是严重烧伤患者中有前景的复合结局指标,可减少临床试验样本量需求,仍需更大规模试验进一步验证。

研究设计与样本

  • 国际多中心前瞻性随机对照试验(RE-ENERGIZE)数据集的二次结局分析,纳入烧伤总面积>20%且随访6个月的患者539例。

主要发现

  • 539例患者中持续性器官功能障碍+死亡第14天发生率为40%,第28天为27%。
  • 两个时间点上有持续性器官功能障碍的存活者较无持续性器官功能障碍的存活者死亡率更高、ICU及住院时间更长、生活质量更低。

关键数值与推荐

  • 检测28天死亡率25%相对风险降低需样本量4492例,而以28天持续性器官功能障碍+死亡为结局仅需1236例。
  • 持续性器官功能障碍定义为需生命支持技术和ICU治疗的器官功能障碍持续存在。

临床怎么用

  • 在严重烧伤临床试验设计中可考虑采用持续性器官功能障碍+死亡作为复合结局指标以提高统计效率。

局限性

  • 本研究为二次结局分析,样本量有限,作者指出需在更大规模临床试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A need exists to improve the efficiency of clinical trials in burn care. The objective of this study was to validate "Persistent Organ Dysfunction" plus death as endpoint in burn patients and to demonstrate its statistical efficiency. METHODS: This secondary outcome analysis of a dataset from a prospective international multicenter RCT (RE-ENERGIZE) included patients with burned total body surface area >20% and a 6-month follow-up. Persistent organ dysfunction was defined as persistence of organ dysfunction with life-supportiing technologies and ICU care. RESULTS: In the 539 included patients, the prevalence of 0p p+ pdeath was 40% at day 14 and of 27% at day 28. At both timepoints, survivors with POD (vs. survivors without POD) had a higher mortality rate, longer ICU- and hospital-stays, and a reduced quality of life. POD + death as an endpoint could result in reduced sample size requirements for clinical trials. Detecting a 25% relative risk reduction in 28-day mortality would require a sample size of 4492 patients, whereas 1236 patients would be required were 28-day POD + death used. CONCLUSIONS: POD + death represents a promising composite outcome measure that may reduce the sample size requirements of clinical trials in severe burns patients. Further validation in larger clinical trials is warranted. STUDY TYPE: Prospective cohort study, level of evidence: II.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Stoppe C, Hill A, Day AG, et al. The initial validation of a novel outcome measure in severe burns- the Persistent Organ Dysfunction +Death: Results from a multicenter evaluation. Burns. 2020. PMID: 33288334. doi:10.1016/j.burns.2020.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。